In every human there are complex biological systems working to keep physiological functions in order. When these biochemical systems are functioning optimally, they maintain optimal mood, help maintain appropriate levels of immunity, proper digestion, regular sleep, brain function, etc. The housekeeping properties of these systems have an important role in modulating health and disease. One of these systems is the endocannabinoid system (ECS). The system is built out of G protein-coupled receptors called (CB1 and CB2 “receptors”) and the “endocannabinoids” that bind to them. The ECS maintains normal cerebral and physiological function.
Human clinical trials and animal studies show that stimulating this biochemical system can have both highly beneficial health effects and few negative side effects. Basic research experiments with genetically modified mice, which are created without CB1 or CB2 receptors, have shown that without this biochemical system, the animals (and presumably, humans) would probably die at birth.4-7 Studies in both humans and animals demonstrate that blocking this biochemical system can result in dreadful consequences, including, but not limited to, depression, stress, nausea, vomiting, diarrhea, anxiety, and even increased tendency for suicide.8-11 The only antagonist drug ever to be marketed to humans that blocked the cannabinoid receptors — Acomplia® (rimonabant; Sanofi-Aventis; Paris, France) — was quickly withdrawn from the market due to its negative health consequences.